# A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

> **NCT03694444** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amyndas Pharmaceuticals S.A.** · enrollment: 39 (actual)

## Conditions studied

- Gingivitis

## Interventions

- **DRUG:** AMY-101
- **OTHER:** Water for injection

## Key facts

- **NCT ID:** NCT03694444
- **Lead sponsor:** Amyndas Pharmaceuticals S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-22
- **Primary completion:** 2020-08-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694444, "A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03694444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*